Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co Buyback Yield % Chart
SHSE:688513 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Buyback Yield % of 0.00 as of Aug. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #999999 out of 735 companies in the Biotechnology industry.
Is Chengdu Easton Biopharmaceuticals Co's Buyback Yield % too high?
Chengdu Easton Biopharmaceuticals Co's current Buyback Yield % is 0.00. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #999999 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #999999 out of 735 companies for Buyback Yield %. This places Chengdu Easton Biopharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥46.22, compared to a current price of ¥44.68 — trading 3.3% below its estimated fair value. The current Buyback Yield % is 0.00. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Buyback Yield % is 0.00 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥44.68 is trading 3.3% below its estimated GF Value™ of ¥46.22.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:688513:
Buyback Yield %: 0.00
GF Value™: ¥46.22 vs. price of ¥44.68 (3.3% below fair value)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
88GF Score
Get the complete analysis for SHSE:688513
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
